www.ijarp.com ISSN 2456-9992 Page: 01-18

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

AI IN PHARMACEUTICAL MARKETING

***Mr. Mudassir Ansari, Devashish Jenna (Assistant Professor)**

India.

Article Received: 10 March 2026, Article Revised: 30 March 2026, Published on: 20 April 2026

***Corresponding Author: Mr. Mudassir Ansari**
India.

DOI: https://doi-doi.org/101555/ijarp.4097

ABSTRACT

Artificial intelligence (AI) has emerged as a transformative technology that integrates human intelligence with advanced computational capabilities to address complex challenges in the pharmaceutical field. In recent years, AI has significantly influenced drug discovery, formulation development, and the evaluation of pharmaceutical dosage forms. By enabling the analysis of large and complex datasets, AI facilitates faster identification of potential drug candidates and improves the efficiency and success rate of drug development and approval processes.

Furthermore, AI-driven approaches help reduce research and development costs through process optimization and predictive modeling. The integration of AI in personalized medicine allows for the analysis of patient-specific data, leading to improved therapeutic outcomes, enhanced treatment precision, and better patient adherence.

This review article highlights the diverse applications of AI in pharmaceutical technology, including drug discovery, drug delivery system design, process optimization, and pharmacokinetic and pharmacodynamic studies. It also discusses the advantages, limitations, and future potential of AI-based methodologies. Continued advancements and investments in AI are expected to further revolutionize the pharmaceutical industry and open new avenues for innovation.

KEYWORDS: Artificial Intelligence (AI), Machine Learning Algorithms, Drug Discovery, Patient Data Analysis, Process Optimization, Personalized Medicine

INTRODUCTION

Artificial Intelligence (AI), once considered a concept of science fiction, now plays a central role in modern technological advancements. It is an interdisciplinary field that involves the

development of algorithms and high-speed computational systems, enabling machines to learn from data and interactions with their environment. This capability allows machines to solve problems, make decisions, and improve performance over time.

The fundamental principle of AI lies in the simulation of human intelligence, enabling machines to perform tasks such as reasoning, learning, problem-solving, perception, and language understanding. The term "Artificial Intelligence" was first coined by John McCarthy in 1955, who is widely regarded as the father of AI and also developed the first AI programming language, Lisp.

In the current era, the impact of AI is profound. Its integration with other emerging technologies is driving a transformative shift across multiple sectors, particularly in healthcare and pharmaceutical sciences. AI is revolutionizing pharmacy practice by improving medication management, streamlining workflows, and enhancing patient outcomes. It enables pharmacists to make informed decisions using real-time, data-driven insights.

One of the most significant applications of AI in pharmacy is in medication management. AI-supported decision systems assist pharmacists in selecting appropriate drugs and dosages, while also identifying potential drug interactions and adverse drug reactions. These technologies enhance clinical decision-making and reduce the likelihood of medication errors.

AI is also transforming the drug discovery process by enabling the analysis of large and complex datasets. This accelerates the identification of potential drug candidates and improves the accuracy of predictions, ultimately reducing the time required for drug development. As a result, new therapeutic options are being explored for diseases such as cancer, Acquired Immunodeficiency Syndrome, cardiovascular diseases, and stroke.

Furthermore, AI plays a key role in advancing personalized medicine. By analyzing individual patient data, including genetic profile, medical history, and lifestyle, AI helps in designing tailored treatment plans. This approach enhances treatment efficacy while minimizing adverse drug reactions.

AI also contributes to improving pharmacy operations by simplifying workflows and reducing administrative burdens. Technologies such as robotic dispensing systems enhance the accuracy and efficiency of medication dispensing. Automated systems ensure proper packaging and labeling of medicines, thereby minimizing human errors. Several pharmaceutical companies, including Pfizer, RxPrism Health Systems, and Tricog Health, have adopted AI-driven solutions to improve operational efficiency.

In addition, AI-based inventory management systems help pharmacies maintain optimal stock levels by predicting drug demand and minimizing wastage. These intelligent systems ensure better resource utilization and uninterrupted availability of essential medicines.

Despite its numerous advantages, the integration of AI in pharmacy also raises concerns regarding data privacy, ethical considerations, and the need for skilled professionals to manage advanced technologies. Therefore, while AI holds immense potential to transform the pharmaceutical industry, careful implementation and regulation are essential to maximize its benefits.

AI plays a crucial role in enhancing patient safety within pharmacy practice. The integration of AI technologies enables the detection and prevention of medication errors, such as incorrect dosages and harmful drug interactions, thereby reducing adverse drug reactions (ADRs) and hospital admissions. AI systems can continuously monitor patient data to identify early signs of adverse effects, allowing timely clinical intervention and preventing serious complications.

In addition, AI-powered tools support medication adherence by tracking patient compliance and providing reminders, alerts, and personalized notifications. This improves adherence to prescribed drug regimens and ultimately enhances therapeutic outcomes. By ensuring accurate medication use and timely interventions, AI significantly contributes to safer and more effective patient care.

Despite these advantages, the implementation of AI in pharmacy practice presents several challenges. The initial cost of integrating AI technologies can be substantial, particularly for smaller pharmacies with limited financial resources. Furthermore, the successful adoption of AI requires adequate training and education, as some pharmacists may be hesitant to rely on AI-driven systems due to a lack of familiarity or trust.

Looking ahead, AI holds great promise for the future of the pharmaceutical industry. As the technology continues to evolve, it is expected to deliver more advanced, precise, and efficient solutions in pharmacy practice. Collaboration between pharmacists, AI developers, and healthcare professionals will be essential to drive innovation and tailor AI tools to meet specific clinical and operational needs.

The World Health Organization recognizes that AI has significant potential to advance global health and support the achievement of universal health coverage. However, it also highlights the importance of addressing ethical concerns, data privacy issues, and potential risks associated with AI implementation to ensure its safe and equitable use.

AI is also transforming pharmaceutical supply chain management by improving efficiency, transparency, and demand forecasting. Additionally, AI tools enhance consistency in patient care by minimizing variability in drug manufacturing and delivery processes. Automation of routine tasks, such as documentation and record-keeping, further improves productivity, allowing healthcare professionals to focus more on patient-centered services.

Overall, AI is revolutionizing pharmacy practice by enhancing patient safety, improving treatment outcomes, optimizing workflows, and enabling personalized care. However, to fully realize its potential, it is essential to address existing challenges, ensure proper training, and promote collaborative efforts. With careful implementation, AI can significantly improve the quality and efficiency of pharmaceutical care and contribute to better healthcare outcomes.

2. Different Types of Artificial Intelligence

Artificial Intelligence **can be categorized based on** capabilities**,** functionalities**, and** underlying technologies**.**

2.1 Based on Capabilities

• Narrow AI (Weak AI):

Narrow AI is designed to perform specific tasks within a limited scope, such as facial recognition, internet searches, or autonomous driving. Most current AI systems fall into this category, including advanced programs capable of playing complex games like chess and Go. These systems operate within predefined contexts and cannot perform beyond their programmed capabilities.

• General AI (Strong AI):

General AI refers to a theoretical form of AI with human-like cognitive abilities. It can understand, learn, and apply knowledge across a wide range of tasks, including unfamiliar situations, without human intervention. Such systems would possess the ability to reason, adapt, and solve problems autonomously.

• Superintelligent AI:

Superintelligent AI represents a hypothetical future stage in which machines surpass human intelligence in all aspects, including creativity, decision-making, and problem-solving. This form of AI remains speculative and has not yet been realized.

2.2 Based on Functionalities

• Reactive Machines:

Reactive AI systems do not store past experiences or memories. They respond only to current inputs. A well-known example is Deep Blue, developed by IBM, which defeated Garry Kasparov in 1997 by analyzing the present state of the chessboard and selecting optimal moves.

• Limited Memory:

Limited memory AI systems can learn from historical data and use past experiences to improve decision-making. Most modern AI applications, including virtual assistants and self-driving vehicles, fall into this category.

• Theory of Mind:

This is an advanced form of AI that is still under research. It aims to understand human emotions, beliefs, intentions, and social interactions, enabling machines to respond more naturally and effectively in human-centered environments.

• Self-Aware AI:

Self-aware AI is a futuristic concept in which machines possess consciousness, self-awareness, and emotions. Such systems would be capable of independent thinking and decision-making, but this type of AI remains theoretical.

2.3 Based on Technology

• Machine Learning (ML):

Machine Learning is a subset of AI that enables systems to learn from data and improve performance without explicit programming. It uses statistical techniques to identify patterns and make predictions.

• Deep Learning:

Deep Learning is an advanced branch of ML that uses multi-layered neural networks to process large datasets. It is widely used in applications such as image recognition, speech processing, and voice assistants.

• Natural Language Processing (NLP):

Natural Language Processing allows machines to understand, interpret, and generate human language. It is used in chatbots, translation tools, and sentiment analysis systems.

• Robotics:

Robotics involves the design and development of intelligent machines capable of performing physical tasks with minimal human intervention.

• Computer Vision:

Computer Vision enables machines to interpret and analyze visual information from images and videos. It is used in medical imaging, surveillance, and industrial automation.

• Expert Systems:

Expert systems are AI-based programs that mimic the decision-making abilities of human experts using rule-based logic in specific domains.

3. Background

3.1 Core Concepts of Artificial Intelligence

Artificial Intelligence encompasses a range of foundational concepts that contribute to the development of intelligent systems. These concepts work together to create technologies that are transforming industries and everyday life.

3.2 Machine Learning

Machine Learning is a core component of AI that enables systems to learn from data and improve their performance over time without explicit programming. It relies on statistical models and algorithms to identify patterns, make predictions, and support decision-making processes. AI and ML share a complementary relationship, where machine learning provides the computational techniques and AI offers the broader framework for intelligent behavior.

3.3 Real-World Applications of Machine Learning

• Predictive Analytics:

Machine learning algorithms are used in the financial sector to forecast market trends, assess risks, and identify potential investment opportunities.

• Recommendation Systems:

ML powers recommendation engines used by companies like Amazon and Netflix, which analyze user behavior and preferences to suggest products, movies, or content.

3.4 Fraud Detection

Machine Learning (ML) plays a crucial role in fraud detection by analyzing large and complex datasets to identify unusual patterns and suspicious activities. These systems are widely used across industries such as finance, insurance, and healthcare to enhance security, reduce financial losses, and ensure data integrity.

3.5 Deep Learning

Deep Learning is an advanced subset of Machine Learning that utilizes multi-layered artificial neural networks to analyze data at multiple levels of abstraction. It is particularly effective for handling large-scale datasets and delivers high accuracy and efficiency.

Applications:

- **Image Recognition:** Used in medical imaging, diagnostics, and surveillance systems
- **Speech Recognition:** Enables voice assistants and speech-to-text technologies
- **Facial Recognition:** Applied in security systems and identity verification

3.6 Natural Language Processing (NLP)

Natural Language Processing (NLP) enhances the ability of machines to process, understand, and respond to human language. It enables effective interaction between humans and computers by allowing machines to interpret and generate meaningful language outputs.

Industry Applications:

- **Customer Service:**

Chatbots and virtual assistants use NLP to understand and respond to user queries efficiently.

- **Healthcare:**

NLP converts unstructured clinical notes into structured, analyzable data, supporting predictive analytics and clinical decision-making.

- **Legal Sector:**

NLP tools analyze large volumes of legal documents to extract relevant information and insights.

3.7 Autonomous Systems

Autonomous systems are AI-driven technologies capable of performing tasks independently without human intervention. These systems rely heavily on deep learning and real-time data processing.

Example:

Autonomous vehicles use AI to navigate complex environments, detect obstacles, and make real-time decisions, improving safety and efficiency.

4. Biostatistics of Artificial Intelligence

The pharmaceutical industry is undergoing rapid transformation due to the increasing integration of Artificial Intelligence (AI) across various processes, ranging from drug discovery to supply chain management. AI technologies are reshaping the industry by enhancing efficiency, accuracy, and productivity.

AI applications are estimated to generate approximately **$350–$410 billion in annual value** for pharmaceutical companies by 2025. Additionally, the pharmaceutical AI market is projected to grow at a **compound annual growth rate (CAGR) of 42.68%**, contributing nearly **$15 billion in growth between 2024 and 2029**. These figures highlight the significant economic potential of AI in the pharmaceutical sector.

Global Adoption of AI in Pharmaceuticals

The United States leads in the adoption of AI within the pharmaceutical industry, with the highest number of AI-related patents, employment opportunities, and investments. Other countries such as the United Kingdom, China, South Korea, and Australia are also actively contributing to advancements in AI-driven pharmaceutical innovations.

Role of Artificial Intelligence in Healthcare

Artificial Intelligence has immense potential to improve healthcare systems and patient outcomes.

AI enables automation of repetitive and time-consuming tasks, allowing clinicians to focus more on patient care. Improved data accessibility supports healthcare professionals in making accurate and timely decisions, aiding in disease prevention and early diagnosis. Real-time data analysis further enhances diagnostic speed and precision.

AI is also being implemented to reduce administrative errors and optimize resource utilization, thereby improving overall healthcare efficiency. The increasing involvement of small and medium enterprises (SMEs) in AI development is making the technology more accessible, practical, and innovative.

CHALLENGES AND LIMITATIONS

Despite its numerous benefits, AI faces certain challenges in healthcare:

- Requirement of continuous human supervision
- Limited consideration of social and behavioral factors
- Gaps in population-based data
- Vulnerability to increasingly sophisticated cyberattacks

5. Current Scenario in the Pharmaceutical Industry

In the present data-driven era, pharmaceutical companies are continuously seeking opportunities to make their processes smarter, faster, and more efficient. Data science serves as the backbone of this transformation, while Artificial Intelligence (AI) and Machine Learning (ML) further enhance the ability to analyze complex datasets with high precision. These technologies are significantly improving decision-making, reducing operational costs, and saving time across the pharmaceutical sector.

The adoption of AI and ML is expected to drive substantial growth in the coming years. Research indicates that the global AI market is projected to reach approximately **$89.8 billion in annual revenue by 2025**, reflecting its increasing importance in modern industries. AI enables computer systems to perform tasks that traditionally require human intelligence, such as data analysis, prediction, and problem-solving. This capability allows pharmaceutical companies to optimize workflows and improve overall efficiency.

Despite these advantages, several organizations still rely on traditional methods and have not fully embraced AI technologies. This reluctance can negatively impact the pharmaceutical industry in multiple ways, including:

- Slower medical data collection and processing
- Limited availability and accessibility of medical records
- Time-consuming and costly drug discovery and research and development (R&D) processes

Therefore, the integration of AI and ML is essential to make healthcare-related processes more seamless, cost-effective, and efficient.

In recent years, the use of AI in the pharmaceutical industry has increased rapidly. Surveys indicate that nearly **80% of pharmaceutical and life sciences professionals** are now utilizing AI in drug discovery. Furthermore, AI has the potential to significantly reduce drug development timelines—from approximately **5–6 years to nearly one year**—thereby accelerating the availability of new therapies.

Applications of AI in the Pharmaceutical Industry

1. **Quality Control and Quality Assurance (QA & QC):**

   AI enhances quality management by detecting defects, ensuring compliance with regulatory standards, and maintaining consistency in pharmaceutical manufacturing processes.

2. Pharmaceutical Product Management:

- Market positioning
- Market analysis and prediction
- Product costing and pricing strategies

3. Pharmaceutical Product Development:

- Assistance in selecting appropriate excipients
- Monitoring and optimizing manufacturing processes
- Ensuring in-process quality specifications

4. Clinical Trial Design and Monitoring:

- Subject selection and patient recruitment
- Market analysis and predictive modeling
- Cost estimation and resource optimization

6. Applications of AI in Pharmaceutical Industry

6.1 Drug Discovery

Artificial Intelligence plays a vital role in modern drug discovery by improving efficiency and accuracy across various stages:

- **Drug Design:**

AI assists in understanding drug–protein interactions and predicting targeted protein structures, enabling the design of more effective drug molecules.

- **Drug Screening:**

AI algorithms help in:

  - Toxicity prediction
  - Bioactivity prediction
  - Physicochemical property prediction

This accelerates the identification of potential drug candidates and reduces failure rates.

6.2 Pharmaceutical Manufacturing

AI is transforming manufacturing processes by enhancing automation and precision:

- **Automated Manufacturing:**

AI-driven systems ensure consistency, reduce human errors, and improve production efficiency.

- **Personalized Manufacturing:**

Enables the development of patient-specific formulations tailored to individual needs.

- **Process Optimization:**

AI correlates manufacturing errors with process parameters, allowing real-time monitoring and corrective actions.

7. Pharmaceutical Companies Using AI

Several leading pharmaceutical companies are leveraging AI to revolutionize drug discovery, clinical trials, and manufacturing:

- **Sanofi**

Partnered with Aily Labs to develop the "Plai" platform for data-driven decision-making across drug development. It has also collaborated with Hillo for AI-enabled connected insulin devices.

- **Pfizer**

Utilized AI and supercomputing from IBM to accelerate the development of Paxlovid, significantly reducing computational time. It has also collaborated with CytoReason to model the human immune system.

- **Novartis**

Engaged in over 150 AI projects and partnered with Microsoft and NVIDIA to scale AI applications.

- **Janssen Pharmaceuticals**

Uses AI platforms like Trials360.ai to optimize clinical trial design and improve patient outcomes.

- **AstraZeneca**

Collaborated with BenevolentAI to identify therapeutic targets for diseases such as chronic kidney disease and idiopathic pulmonary fibrosis.

- **Bristol Myers Squibb**

Partnered with Exscientia to accelerate small-molecule drug discovery.

- **Bayer**

Collaborates with Exscientia on cardiovascular and oncology drug development.

- **Merck**

Engaged in AI collaborations with BenchSci, Atomwise, and C4 Therapeutics.

- **GlaxoSmithKline**

Works with Insilico Medicine and Cloud Pharmaceuticals for drug design and target identification.

- **Roche**

Partnered with Recursion Pharmaceuticals and established an AI innovation hub.

- **Eli Lilly**

Expanding AI-driven automation and digital workforce to enhance productivity and accelerate drug development processes.

8. Use of AI in Pharma

8.1 Drug Discovery and Design

AI supports various stages of drug development, including:

- Target identification and validation
- Phenotypic and multi-target drug discovery
- Drug repurposing
- Biomarker identification

AI reduces the time required for drug approval and market entry, resulting in significant cost savings and improved patient access to therapies.

For example, AI can analyze electronic medical records (EMRs), genomic data, and other "omics" datasets to identify novel drug targets, especially in complex diseases like cancer.

8.2 Drug Repurposing

Drug repurposing involves identifying new therapeutic uses for existing or previously developed drugs. AI enhances this process by:

- Analyzing large datasets to identify new indications
- Reducing development risks and costs
- Minimizing unexpected toxicity

This approach is particularly valuable for pharmaceutical companies with limited budgets, as it accelerates drug availability while maintaining safety and efficacy.

8.3 Drug Adherence and Dosage Monitoring

Ensuring patient compliance with drug regimens is a major challenge in clinical trials and routine therapy. Non-adherence to prescribed protocols can compromise study outcomes and may lead to inaccurate conclusions or patient exclusion.

Artificial Intelligence provides effective solutions through:

- **Remote patient monitoring systems**
- **AI-based algorithms for evaluating adherence patterns**
- **Real-time alerts and reminders for medication intake**

These tools help ensure that participants follow prescribed dosage schedules, thereby improving the reliability of clinical trial results and enhancing therapeutic outcomes.

8.4 Rare Diseases and Personalized Medicine

AI is playing a transformative role in the detection and treatment of rare diseases and in advancing personalized medicine. By integrating data from medical imaging, patient biology, genomics, and clinical records, AI can:

- Detect diseases such as cancer at earlier stages
- Predict potential health risks based on genetic profiles
- Develop individualized treatment plans

A notable example is IBM Watson for Oncology, which analyzes patient medical history and clinical data to recommend personalized treatment strategies.

AI also enables the development of tailored drug therapies by analyzing:

- Patient-specific test results
- Previous drug responses
- Historical data on adverse drug reactions

This approach improves treatment efficacy while minimizing side effects.

9. Limitations of AI in Medicine

Despite its numerous advantages, AI in medicine has certain limitations that must be addressed for its effective implementation.

9.1 Requirement of Human Supervision

Although AI systems have advanced significantly, human oversight remains essential. For instance, robotic systems in surgery operate based on programmed logic but lack human

empathy and clinical intuition. Healthcare professionals can identify subtle behavioral and clinical signs that AI systems may overlook.

AI systems require continuous input, validation, and monitoring by experts to ensure accuracy and reliability. Collaboration between healthcare professionals and technology experts is crucial for improving AI performance and trustworthiness.

9.2 Limited Consideration of Social Factors

AI systems primarily rely on clinical and quantitative data, often overlooking important social, economic, and behavioral factors that influence patient care. For example:

- A treatment plan suggested by AI may not consider a patient's financial condition
- Accessibility to healthcare facilities may not be accounted for
- Cultural and personal preferences may be ignored

Such limitations highlight the need for integrating holistic patient data into AI systems.

9.3 Data Privacy and Security Concerns

The use of AI in healthcare raises significant concerns regarding data privacy and security. While companies like Amazon and Apple collect and process large amounts of user data, healthcare systems must adhere to strict regulatory standards.

Challenges include:

- Secure handling of sensitive patient data
- Compliance with healthcare regulations
- Risk of data breaches and cyberattacks

These concerns must be addressed to ensure safe and ethical use of AI technologies in medicine.

9.4 Regulatory and Social Restrictions

Regulatory frameworks and ethical considerations can limit the implementation of AI in healthcare. Strict data governance policies, compliance requirements, and societal concerns regarding data usage may restrict the seamless integration of AI technologies into medical practice.

9.5 Risk of Unemployment

While AI has the potential to reduce workload and operational costs, it may also lead to job displacement. Roles involving repetitive and routine tasks are particularly at risk. According

to the World Economic Forum, AI was projected to create approximately 58 million jobs while displacing around 75 million jobs globally. This imbalance highlights the need for workforce reskilling and adaptation.

9.6 Possibility of Inaccuracies

AI systems rely heavily on large datasets for training and decision-making. In cases where data is limited or biased—such as rare diseases, underrepresented populations, or specific environmental conditions—there is a risk of inaccurate predictions or misdiagnosis. These inaccuracies can significantly affect treatment outcomes, especially in drug prescription and clinical decision-making.

9.7 Security Risks

AI systems depend on interconnected data networks, making them vulnerable to cybersecurity threats. The emergence of offensive AI technologies increases the risk of data breaches and system manipulation. According to Forrester Consulting, a significant proportion of security professionals consider offensive AI to be an emerging threat. Therefore, robust cybersecurity measures are essential to ensure safe AI implementation.

10. CONCLUSION

Artificial Intelligence is transforming pharmaceutical technologies by enabling targeted, personalized, and adaptive approaches to drug development and healthcare delivery. Its capabilities in data analysis, pattern recognition, and process optimization have significantly enhanced drug efficacy, minimized adverse effects, and improved patient compliance.

AI-based methods have revolutionized the fields of pharmacokinetics and pharmacodynamics by providing efficient, cost-effective, and data-driven solutions. These models can accurately predict pharmacokinetic parameters, simulate drug absorption, distribution, metabolism, and excretion, and optimize drug dosage and administration routes.

Furthermore, AI-driven computational pharmaceutics has streamlined drug formulation development and enabled the design of personalized therapies. It reduces reliance on extensive animal studies and clinical trials, thereby increasing productivity while conserving time and resources.

Despite its numerous advantages, AI faces challenges such as data limitations, ethical concerns, security risks, and the need for human oversight. Addressing these challenges through proper regulation, interdisciplinary collaboration, and continuous technological advancements is essential.

In conclusion, AI holds immense potential to revolutionize the pharmaceutical industry and healthcare systems. With responsible implementation, it can significantly improve patient outcomes, enhance research efficiency, and pave the way for innovative and sustainable healthcare solutions.

Artificial Intelligence continues to demonstrate immense potential in transforming pharmaceutical sciences by improving drug formulation, optimizing dosage forms, and reducing associated risks. Its application in computational pharmaceutics enhances drug manufacturing processes, ensuring improved efficiency, consistency, and better patient outcomes. AI also supports rapid decision-making, cost reduction, and optimization of production processes, ultimately enabling faster development of high-quality pharmaceutical products with reliable batch-to-batch consistency.

Furthermore, AI contributes significantly to the selection and optimization of appropriate dosage forms, along with predictive market analysis, which supports better planning and resource utilization. Despite these advantages, several challenges hinder its widespread adoption, including the lack of skilled personnel, limited financial resources in smaller organizations, concerns about job displacement, and skepticism regarding AI-generated data, particularly due to the "black box" nature of some AI models.

Currently, the number of drugs fully developed using AI-based approaches remains limited, and several technical, ethical, and regulatory challenges persist. However, with ongoing advancements, increased investment, and improved understanding of AI systems, it is highly likely that AI will become an indispensable tool in the pharmaceutical industry in the near future.

REFERENCES:

1. Krikorian, G.; Torreele, E. We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. Health Hum. Rights 2021, 23, 119–127. [Google Scholar]
2. Chavda, V.P.; Vihol, D.; Patel, A.; Redwan, E.M.; Uversky, V.N. Introduction to Bioinformatics, AI, and ML for Pharmaceuticals. In Bioinformatics Tools for Pharmaceutical Drug Product Development; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2023; pp. 1–18. [Google Scholar]
3. Scannell, J.W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the Decline in Pharmaceutical R&D Efficiency. Nat. Rev. Drug Discov. 2012, 11, 191–200. [Google Scholar] [CrossRef] [PubMed]

4. Munos, B. Lessons from 60 Years of Pharmaceutical Innovation. Nat. Rev. Drug Discov. 2009, 8, 959–968. [Google Scholar] [CrossRef]
5. Mak, K.-K.; Pichika, M.R. Artificial Intelligence in Drug Development: Present Status and Future Prospects. Drug Discov. Today 2019, 24, 773–780. [Google Scholar] [CrossRef]
6. Biggest Challenges Facing the Pharmaceutical Industry in 2023. Available online: https://www.pssindia.com/2023/01/ 23/biggest-challenges-facing-thepharmaceutical-industry-in2023/ (accessed on 5 May 2023).
7. Chavda, V.; Valu, D.; Parikh, P.; Tiwari, N.; Chhipa, A.; Shukla, S.; Patel, S.; Balar, P.; Paiva-Santos, A.; Patravale, V. Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants. Vaccines 2023, 11, 374. [Google Scholar] [CrossRef]
8. Vora, L.K.; Gholap, A.D.; Jetha, K.; Thakur, R.R.S.; Solanki, H.K.; Chavda, V.P. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics 2023, 15, 1916. https://doi.org/10.3390/pharmaceutics150 71916
9. Dwivedi, Y. K., Hughes, L., Ismagilova, E., Aarts, G., Coombs, C., Crick, T., Duan, Y., Dwivedi, R., Edwards, J., Eirug, A., Galanos, V., Ilavarasan, P. V., Janssen, M., Jones, P., Kar, A. K., Kizgin, H., Kronemann, B., Lal, B., Lucini, B., . . . Williams, M. D. (2019). Artificial Intelligence (AI): Multidisciplinary perspectives on emerging challenges, opportunities, and agenda for research, practice and policy. International Journal of Information Management, 57, 101994. https://doi.org/
2. 10.1016/j.ijinfomgt.2019.08.0 02 10.Curioni-Fontecedro, A. (2017). A new era of oncology through artificial intelligence. ESMO Open, 2(2), e000198. https://doi.org/10.1136/esmoopen-2017- 000198
10. Biggest Challenges Facing the Pharmaceutical Industry in 2023. Available online: https://www.pssindia.com/2023/01/ 23/biggest-challenges-facing-thepharmaceutical-industry-in2023/ (accessed on 5 May 2023).
11. Patel, V., & Shah, M. (2021). Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine, 2(3), 134–140. https://doi.org/10.1016/j.imed.2021.10.001
12. Amisha, Malik, P., Pathania, M., &Rathaur, V. K. (2019). Overview of artificial intelligence in medicine. Journal of Family Medicine and Primary Care, 8(7), 2328. https://doi.org/10.4103/jfmpc.jfmpc_440_1 9

13. Patel, V. L., Shortliffe, E. H., Stefanelli, M., Szolovits, P., Berthold, M. R., Bellazzi, R., & Abu-Hanna, A. (2008). The coming of age of artificial intelligence in medicine. Artificial Intelligence in Medicine, 46(1), 5– 17. https://doi.org/10.1016/j.artmed.2008.07.017
14. Shortliffe, E. H. (2019). Artificial Intelligence in Medicine: Weighing the Accomplishments, Hype, and Promise. Yearbook of Medical Informatics, 28(01), 257–262. https://doi.org/10.1055/s-0039- 1677891